Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Unusually-High Trading Volume - What's Next?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) saw unusually-high trading volume on Monday . Approximately 9,916,028 shares traded hands during mid-day trading, a decline of 16% from the previous session's volume of 11,771,491 shares.The stock last traded at $5.68 and had previously closed at $5.76.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Morgan Stanley reduced their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. KeyCorp lowered their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Tuesday, April 8th. Finally, Leerink Partners reduced their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research report on Friday, February 28th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $8.20.

Recursion Pharmaceuticals Stock Performance

The business has a fifty day moving average of $6.62 and a 200-day moving average of $6.79. The company has a market cap of $2.21 billion, a PE ratio of -3.59 and a beta of 1.00. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $4.60 million for the quarter, compared to analysts' expectations of $19.04 million. During the same period last year, the firm posted ($0.42) earnings per share. Recursion Pharmaceuticals's quarterly revenue was down 57.8% on a year-over-year basis. Equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently made changes to their positions in RXRX. Stifel Financial Corp increased its position in Recursion Pharmaceuticals by 48.8% during the 3rd quarter. Stifel Financial Corp now owns 161,978 shares of the company's stock valued at $1,067,000 after buying an additional 53,103 shares in the last quarter. Wellington Management Group LLP bought a new position in shares of Recursion Pharmaceuticals during the third quarter valued at $692,000. Barclays PLC increased its holdings in Recursion Pharmaceuticals by 53.9% in the 3rd quarter. Barclays PLC now owns 697,432 shares of the company's stock worth $4,596,000 after buying an additional 244,278 shares in the last quarter. Geode Capital Management LLC lifted its stake in Recursion Pharmaceuticals by 13.7% during the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company's stock valued at $35,803,000 after acquiring an additional 656,003 shares during the period. Finally, Sanctuary Advisors LLC purchased a new position in shares of Recursion Pharmaceuticals during the third quarter valued at approximately $89,000. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.